Projekt

A multicenter, randomized, double-blind, parallel-group,placebo-controlled variable treatment duration studyevaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosisfollowed by extended treatment with open-label BAF312

Automatisch geschlossen · 2016 bis 2020

RSS